BELLICUM PHARMACEUTICALS INC's ticker is and the CUSIP is 079481404. A total of 4 filers reported holding BELLICUM PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $8,991 | -77.1% | 27,245 | -50.0% | 0.00% | – |
| Q4 2022 | $39,232 | +18.9% | 54,490 | +100.0% | 0.00% | – |
| Q3 2022 | $33,000 | +3.1% | 27,245 | 0.0% | 0.00% | – |
| Q2 2022 | $32,000 | -45.8% | 27,245 | 0.0% | 0.00% | – |
| Q1 2022 | $59,000 | +43.9% | 27,245 | 0.0% | 0.00% | – |
| Q4 2021 | $41,000 | -48.8% | 27,245 | 0.0% | 0.00% | – |
| Q3 2021 | $80,000 | -11.1% | 27,245 | 0.0% | 0.00% | – |
| Q2 2021 | $90,000 | – | 27,245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 448,101 | $322,633 | 0.08% |
| Long Focus Capital Management, LLC | 327,692 | $235,938 | 0.02% |
| Boxer Capital, LLC | 56,950 | $41,004 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 45,057 | $32,441 | 0.00% |
| Baker Brothers Advisors | 249,123 | $179,369 | 0.00% |
| SHUFRO ROSE & CO LLC | 12,941 | $9,318 | 0.00% |
| Parallel Advisors, LLC | 10 | $7 | 0.00% |
| MONEY CONCEPTS CAPITAL CORP | 264 | $190 | 0.00% |
| WELLS FARGO & COMPANY/MN | 781 | $562 | 0.00% |
| NORTHERN TRUST CORP | 10,981 | $7,906 | 0.00% |